Thomas Leggett's most recent trade in Stoke Therapeutics Inc was a trade of 2,173 Common Stock done at an average price of $31.3 . Disclosure was reported to the exchange on March 17, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | Thomas E. Leggett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.28 per share. | 17 Mar 2026 | 2,173 | 10,381 (0%) | 0% | 31.3 | 67,980 | Common Stock |
| Stoke Therapeutics Inc | Thomas E. Leggett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.74 per share. | 17 Mar 2026 | 1,274 | 13,476 (0%) | 0% | 32.7 | 41,710 | Common Stock |
| Stoke Therapeutics Inc | Thomas E. Leggett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.38 per share. | 17 Mar 2026 | 922 | 12,554 (0%) | 0% | 33.4 | 30,772 | Common Stock |
| Stoke Therapeutics Inc | Thomas E. Leggett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 31.79 per share. | 17 Mar 2026 | 172 | 10,209 (0%) | 0% | 31.8 | 5,468 | Common Stock |
| Stoke Therapeutics Inc | Thomas E. Leggett | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 32.84 per share. | 17 Mar 2026 | 37 | 10,172 (0%) | 0% | 32.8 | 1,215 | Common Stock |
| Stoke Therapeutics Inc | Thomas E. Leggett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 14,750 | 14,750 (0%) | 0% | 0 | Common Stock | |
| Stoke Therapeutics Inc | Thomas E. Leggett | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2026 | 14,750 | 44,250 | - | - | Restricted Stock Units | |
| Stoke Therapeutics Inc | Thomas E. Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Thomas E. Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2026 | 40,000 | 40,000 | - | - | Restricted Stock Units | |
| Stoke Therapeutics Inc | Thomas E. Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 89,000 | 89,000 | - | - | Employee Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Thomas E. Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2025 | 59,000 | 59,000 | - | - | Restricted Stock Units | |
| Stoke Therapeutics Inc | Thomas Leggett | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 396,200 | 396,200 | - | - | Stock Option (Right to Buy) |